Dry eye market seen hitting $10.3 billion by 2035

Market Research Future projects the global dry eye syndrome market will grow from $7.09 billion in 2026 to $10.30 billion by 2035, driven by heavier screen use, aging populations and a shift toward prescription therapies. The report points to faster adoption of diagnostics, tele-ophthalmology and preservative-free treatments across major regions.

Why it matters: - The dry eye market is moving from a symptom-relief category to a chronic disease-treatment market. - That shift could expand prescription use, boost reimbursement coverage and lift demand for diagnostic tools through 2035. - Rising screen exposure and aging populations are widening the patient pool across developed and emerging markets.

What happened: - Market Research Future projected the global Dry Eye Syndrome Market will rise from USD 7.09 billion in 2026 to USD 10.30 billion by 2035. - The forecast implies a 4.25% CAGR from 2026 to 2035. - The market base was estimated at USD 6.80 billion in 2025. - The report said the growth story is being driven by screen exposure, demographic aging and a pipeline of new therapies.

The details: - Screen time for working-age adults now exceeds 10.5 hours a day in the US and 8.7 hours across the EU, according to an American Optometric Association 2024 survey. - Digital eye strain is estimated to affect 65% of office workers globally. - The report said blink-rate reduction linked to near-work exposure worsens tear-film instability and dry eye symptoms. - The UN projects people aged 65 and older will make up 16% of the global population by 2030, up from 10% in 2022. - Dry eye affects roughly 30% of adults over 50 and nearly 50% of adults over 75. - The WHO’s recognition of dry eye as a chronic condition has helped frame the disease as a long-term management category. - The global prevalence rate now exceeds 300 million diagnosed individuals, and screening programs in Japan and South Korea are adding more cases. - Prescription therapies held the largest treatment-modality share in 2025 at about 45.3%. - Evaporative dry eye accounted for about 56.1% of revenue in 2025. - Eye drops led dosage forms with about 70.2% of revenue in 2025. - Hospital pharmacies held about 65.9% of distribution share in 2025. - Online pharmacies were the fastest-growing channel, with a projected 10.58% CAGR from 2026 to 2035. - Ointments and gels are the fastest-growing dosage form, with an expected 8.60% CAGR over the forecast period. - Aqueous-deficient dry eye is the fastest-growing disease type, projected at 8.01% CAGR from 2026 to 2035.

Between the lines: - The market is being pulled toward earlier diagnosis and more targeted treatment, not just artificial tears. - AI-powered diagnostic tools are catching dry eye at subclinical stages, which may shift patients into preventive therapy earlier. - Payer pressure is also changing the market structure. - The report said preventing a single corneal ulceration event can save payers about USD 8,000 to USD 12,000 per patient in Europe. - That economics favors prescription anti-inflammatory and immunomodulatory therapies over delayed intervention. - The market remains fragmented, with no company above 12% revenue share and the top five holding about 38% to 42% combined. - The competitive field is being shaped more by innovation, formulary access and geography than by scale alone. - Alcon received FDA approval in May 2025 for TRYPTYR® (acoltremon ophthalmic solution) 0.003%, a first-in-class TRPM8 receptor agonist designed to stimulate natural tear production.

What's next: - By 2030, the report expects precision ophthalmology and biomarker-driven therapy to become central to dry eye care. - About 40% of newly diagnosed moderate-to-severe patients are expected to receive objective diagnostic staging followed by matched biologic therapy by 2030. - The 2026 TFOS DEWS III framework is expected to standardize screening tools such as the OSDI-6. - North America remains the largest regional market at about 38.0% share in 2025, while Asia-Pacific is the fastest-growing region at 7.84% CAGR from 2026 to 2035. - Europe is expected to face more packaging and sustainability requirements starting in 2027, which could reshape procurement and product design. - The report pointed to tele-ophthalmology, reimbursement expansion and preservative-free formulations as key growth areas over the next decade.

The bottom line: - Dry eye is becoming a large, chronic and increasingly treated ophthalmology market, with the biggest growth coming from diagnosis, prescription adoption and aging-screened populations.